Approvals· July 3, 2026 · 17 min read
Icotyde (icotrokinra) FDA approval and oral IL-23 psoriasis access
By Ran Chen#FDA Approval#Dermatology#Immunology
Topic
Immunology
IL-23, IL-17, JAK, TNF inhibitors, biologic access, payer coverage, step therapy, and immunology drug comparison.
Evidence· June 13, 2026 · 11 min read
EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy
By Ran Chen#Immunology#Clinical Evidence#Pivotal Trials
Pipeline· June 3, 2026 · 9 min read
Cendakimab PDUFA preview: IL-13 inhibitor for eosinophilic esophagitis
By Ran Chen#PDUFA Date#FDA Approval#Immunology
Pricing & Access· May 31, 2026 · 12 min read
Renewal denial after stable disease: documenting continued benefit
Biosimilars· May 27, 2026 · 9 min read
Actemra biosimilars access guide: IV vs SC routing and payer switching
By Ran Chen#Biosimilars#Immunology#HCPCS Coding
Pricing & Access· May 27, 2026 · 10 min read
Cosentyx access guide: secukinumab coverage and benefit routing
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 27, 2026 · 11 min read
Entyvio access guide: IV vs SC vedolizumab coverage and IBD step therapy
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Biosimilars· May 27, 2026 · 9 min read
Simponi and Simponi Aria biosimilars guide
By Ran Chen#Biosimilars#TNF Inhibitor#Immunology
Pricing & Access· May 27, 2026 · 9 min read
Taltz prior authorization guide for ixekizumab access
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access